Companies › Shanghai BDgene
2 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Hematology, Infectious disease; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| BD111 CRISPR/Cas9-based lentiviral particles targeting HSV-1 genes | HSV1 | Phase 2 | Herpes Simplex Virus Type I Stromal Keratitis | Dec 2026 |
| BD211 Lentiviral vector-transduced autologous CD34+ hematopoietic stem cells expressing βA-T87Q- | – | Phase 1 | β-thalassemia | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06474416 | BD111 | Phase 1 | Herpes Simplex Virus Type I Stromal Keratitis | Infectious disease | Oct 2025 |
| NCT06465550 | BD211 | Phase 1 | β-thalassemia | Hematology | Dec 2026 |
| NCT06474442 | BD111 | Phase 2 | Herpes Simplex Virus Type I Stromal Keratitis | Infectious disease | Dec 2026 |
–
InventVacc Biologicals Serum Institute of India CanSino Biologics Aimei Vacin BioPharm (Zhejiang) Shanghai Xinzhi BioMed
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.